| NCT ID | NCT02994719 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beth Israel Deaconess Medical Center |
| Condition | Parkinson's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2016-03-01 |
| Primary Completion | 2026-06-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2016-03-01 with a primary completion date of 2026-06-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.
Eligibility Criteria
Inclusion Criteria: * Age 18-85 (for both healthy and affected subjects). * Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural instability (UK PD Brain Bank Criteria) (Affected subjects only). * Montreal Cognitive Assessment will be employed to determine whether subjects will need the assent of a legally authorized representative. Subjects with MOCA ≤ 21 will be consented only with the assent of the subject and informed consent of the authorized legal representative (Affected subjects only). * These may include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration (Affected subjects only). * Subjects with assistive devices will be eligible for the study and may use them during the study (Affected subjects only). * Absence of complaints regarding difficulty walking such as arthritic pain, fatigue during walking or slowness of walking (Healthy subjects only). Exclusion Criteria: * Presence of alternative explanation for parkinsonism such as head trauma, drug-induced parkinsonism (affected subjects only). * Currently being treated for major medical illness requiring recent hospitalization (\<14 days) (for both healthy and affected subjects). * Currently participating in another clinical study with an intervention arm (for both healthy and affected subjects). * Inability to consent due to cognitive impairment and absence of legally authorized representative (for both healthy and affected subjects). * Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring hospitalization within the past 90 days, recent myocardial infarction \< 90 days, supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that limit their ability to safely participate in a walking trial (for both healthy and affected subjects).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02994719 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Parkinson's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02994719 currently recruiting?
Yes, NCT02994719 is actively recruiting participants. Contact the research team at vvanderh@bidmc.harvard.edu for enrollment information.
Where is the NCT02994719 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT02994719 clinical trial?
NCT02994719 is sponsored by Beth Israel Deaconess Medical Center. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.